Kaylan M Fenton

Learn More
OBJECTIVE Multiple sclerosis (MS) lesions develop around small, inflamed veins. New lesions enhance with gadolinium on magnetic resonance imaging (MRI), reflecting disruption of the blood-brain barrier (BBB). Single time point results from pathology and standard MRI cannot capture the spatiotemporal expansion of lesions. We investigated the development and(More)
OBJECTIVE To determine the frequency and nature of leptomeningeal contrast enhancement in multiple sclerosis (MS) via in vivo 3-tesla postcontrast T2-weighted, fluid-attenuated inversion recovery (FLAIR) MRI and 7-tesla postmortem MRI-pathology correlation. METHODS Brain MRI, using the postcontrast T2-weighted, FLAIR technique, was prospectively collected(More)
An elevated human T cell lymphotropic virus 1 (HTLV)-1 proviral load (PVL) is the main risk factor for developing HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in HTLV-1 infected subjects, and a high cerebrospinal fluid (CSF) to peripheral blood mononuclear cell (PBMC) PVL ratio may be diagnostic of the condition. However, the standard(More)
The human herpesviruses HHV-6A and HHV-6B have been associated with various neurologic disorders partly due to the detection of elevated viral DNA levels in patients compared to controls. However the reported frequency of these viruses varies widely, likely reflecting differences in PCR methodologies used for detection. Digital droplet PCR (ddPCR) is a(More)
OBJECTIVE To analyze the spectrum and mechanisms of cutaneous adverse events (AEs) in patients with multiple sclerosis treated with daclizumab high-yield process (DAC-HYP). METHODS A total of 31 participants in an institutional review board-approved open-label phase I study of DAC-HYP (NCT01143441) were prospectively evaluated over 42 months for(More)
CD122 is the common beta subunit shared by the receptors for interleukins-2 and-15 (IL-2, IL-15), two cytokines implicated in the immunopathogenesis of HTLV-1 associated myelopathy/ tropical spastic para-paresis (HAM/TSP). Several in vitro findings suggest that CD122 might be a therapeutic target in HAM/TSP: HAM/TSP CD8+ T-cells show increased CD122(More)
Elevated HTLV-1 proviral load (PVL) is thought to be the major risk factor for developing HAM/TSP in HTLV-1 infected subjects, and a high cerebrospinal fluid (CSF) to peripheral blood mononuclear cells (PBMCs) PVL ratio might be diagnostic of the condition. However, the standard method for quantification of HTLV-1 PVL, Real time PCR, has multiple(More)
Therapeutic advance in progressive multiple sclerosis (MS) has been very slow. Based on the transformative role magnetic resonance imaging (MRI) contrast-enhancing lesions had on drug development for relapsing-remitting MS, we consider the lack of sensitive outcomes to be the greatest barrier for developing new treatments for progressive MS. The purpose of(More)
  • 1